(Q37084711)

English

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox

scientific article published on January 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

1 reference

Europe PubMed Central

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

research ethics

0 references

chelation therapy

0 references

George J Kontoghiorghes

1

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

publication date

1 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

1-2

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

1-15

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

The design and development of deferiprone (L1) and other iron chelators for clinical use: targeting methods and application prospects

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Development of tridentate iron chelators: from desferrithiocin to ICL670.

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Deferasirox: An effective once-daily orally active iron chelator

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Do we need more iron-chelating drugs?

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Safety monitoring of cardiac and hepatic systems in beta-thalassemia patients with chelating treatment in Taiwan

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Intramuscular desferrioxamine in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia.

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers

1 reference

https://api.crossref.org/works/10.1080%2F03630260701726533

21 January 2018

Identifiers

10.1080/03630260701726533

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37084711&oldid=1683626093"